thioctic acid has been researched along with Schizophrenia in 20 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 5.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| " The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)." | 5.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required." | 5.42 | Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015) |
| "Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy." | 2.50 | Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. ( Arroll, MA; Neil, J; Wilder, L, 2014) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 1.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| " The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)." | 1.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "Schizophrenia is a chronic mental illness in which mitochondrial dysfunction has been suggested." | 1.43 | Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model. ( Deslauriers, J; Grignon, S; Monpays, C; Sarret, P, 2016) |
| "5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required." | 1.42 | Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. ( de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mishra, A | 1 |
| Reeta, KH | 1 |
| Sarangi, SC | 1 |
| Maiti, R | 1 |
| Sood, M | 1 |
| Dutta, A | 1 |
| Karanth, SS | 1 |
| Bhattacharya, M | 1 |
| Liput, M | 1 |
| Augustyniak, J | 1 |
| Cheung, M | 1 |
| Stachowiak, EK | 1 |
| Stachowiak, MK | 1 |
| Sanders, LLO | 1 |
| de Souza Menezes, CE | 1 |
| Chaves Filho, AJM | 1 |
| de Almeida Viana, G | 1 |
| Fechine, FV | 1 |
| Rodrigues de Queiroz, MG | 1 |
| Gonçalvez da Cruz Fonseca, S | 1 |
| Mendes Vasconcelos, SM | 1 |
| Amaral de Moraes, ME | 1 |
| Gama, CS | 2 |
| Seybolt, S | 1 |
| de Moura Campos, E | 1 |
| Macêdo, D | 4 |
| Freitas de Lucena, D | 1 |
| Sampaio, LRL | 2 |
| Cysne Filho, FMS | 1 |
| de Almeida, JC | 1 |
| Diniz, DDS | 1 |
| Patrocínio, CFV | 1 |
| de Sousa, CNS | 1 |
| Patrocínio, MCA | 2 |
| Vasconcelos, SMM | 2 |
| Ratliff, JC | 1 |
| Palmese, LB | 1 |
| Reutenauer, EL | 1 |
| Tek, C | 1 |
| Deslauriers, J | 2 |
| Racine, W | 1 |
| Sarret, P | 2 |
| Grignon, S | 2 |
| Emsley, R | 2 |
| Chiliza, B | 2 |
| Asmal, L | 2 |
| du Plessis, S | 2 |
| Phahladira, L | 2 |
| van Niekerk, E | 2 |
| van Rensburg, SJ | 2 |
| Harvey, BH | 2 |
| Vidović, B | 2 |
| Milovanović, S | 2 |
| Dorđević, B | 1 |
| Kotur-Stevuljević, J | 2 |
| Stefanović, A | 2 |
| Ivanišević, J | 1 |
| Miljković, M | 1 |
| Spasić, S | 1 |
| Stojanović, D | 1 |
| Pantović, M | 2 |
| Arroll, MA | 1 |
| Wilder, L | 1 |
| Neil, J | 1 |
| Seybolt, SE | 3 |
| Vasconcelos, GS | 1 |
| Ximenes, NC | 1 |
| de Sousa, CN | 1 |
| Oliveira, Tde Q | 1 |
| Lima, LL | 1 |
| de Lucena, DF | 1 |
| Vasconcelos, SM | 1 |
| Monpays, C | 1 |
| Kim, NW | 1 |
| Song, YM | 1 |
| Kim, E | 2 |
| Cho, HS | 2 |
| Cheon, KA | 1 |
| Kim, SJ | 1 |
| Park, JY | 1 |
| Borges, LTN | 1 |
| Barbosa, TM | 1 |
| Matos, NCB | 1 |
| Lima, RF | 1 |
| Oliveira, MN | 1 |
| Gularte, VN | 1 |
| Vale, OCD | 1 |
| Takić, M | 1 |
| Debeljak-Martačić, J | 1 |
| Đorđević, B | 1 |
| ALTSCHULE, MD | 1 |
| GONCZ, RM | 1 |
| HOLLIDAY, PD | 1 |
| Park, DW | 1 |
| Choi, SH | 1 |
| Kim, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia[NCT01355952] | 17 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thioctic acid and Schizophrenia
| Article | Year |
|---|---|
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review.
Topics: Acetylcysteine; Antipsychotic Agents; Ascorbic Acid; Databases, Factual; Diet, Gluten-Free; Dietary | 2014 |
7 trials available for thioctic acid and Schizophrenia
| Article | Year |
|---|---|
Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.
Topics: Antioxidants; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Double-Blind Method; Drug The | 2022 |
α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial.
Topics: Adult; Antioxidants; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2017 |
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Docosahexaenoic Acids; Double-Blind Method; Drug Therapy, | 2014 |
Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia.
Topics: Adult; Advanced Oxidation Protein Products; Antioxidants; Antipsychotic Agents; Blood Glucose; Drug | 2014 |
Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
Topics: Adult; Antioxidants; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; H | 2016 |
Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia.
Topics: Adipokines; Adiponectin; Adult; Blood Glucose; Dietary Supplements; Female; Humans; Insulin; Leptin; | 2017 |
A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Appetite; Blood Glucose; Body Mass Index; Brief Psychiatr | 2008 |
12 other studies available for thioctic acid and Schizophrenia
| Article | Year |
|---|---|
A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology.
Topics: Acetylcarnitine; Brain; Case-Control Studies; Cell Line; Choline; Electron Transport Complex IV; Ele | 2020 |
Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Drug Therapy, C | 2018 |
An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.
Topics: Adolescent; Adult; Aged; Antioxidants; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Obes | 2015 |
Preventive effect of α-lipoic acid on prepulse inhibition deficits in a juvenile two-hit model of schizophrenia.
Topics: Aging; Animals; Disease Models, Animal; Female; Male; Mice, Inbred C57BL; Prefrontal Cortex; Pregnan | 2014 |
Less is more.
Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs | 2014 |
Re: Less is more.
Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs | 2014 |
In response to re: less is more.
Topics: Antioxidants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Psychotropic Drugs | 2015 |
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
Topics: Analysis of Variance; Animals; Antioxidants; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic | 2015 |
Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.
Topics: Animals; Cell Respiration; Corpus Striatum; Electron Transport Complex I; Electron Transport Complex | 2016 |
Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; | 2017 |
Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?
Topics: Antioxidants; Dopamine; Glutathione; Glutathione Disulfide; Humans; Mitochondria; Mitochondrial Memb | 2010 |
Carbohydrate metabolism in brain disease. XI. Effects of thioctic (alpha-lipoic) acid in chronic schizophrenia.
Topics: Brain Diseases; Carbohydrate Metabolism; Carbohydrates; Humans; Schizophrenia; Thioctic Acid; Vitami | 1959 |